Shares of Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) have been assigned a consensus rating of “Hold” from the twelve ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $34.00.
A number of research firms recently weighed in on RHHBY. Credit Suisse Group raised Roche Holdings AG Basel from an “underperform” rating to a “neutral” rating in a research note on Monday, January 28th. Citigroup reissued a “hold” rating on shares of Roche Holdings AG Basel in a report on Monday, November 26th. Goldman Sachs Group lowered Roche Holdings AG Basel from a “conviction-buy” rating to a “buy” rating in a report on Monday, November 19th. Jefferies Financial Group reissued a “buy” rating on shares of Roche Holdings AG Basel in a report on Tuesday, December 11th. Finally, Argus assumed coverage on Roche Holdings AG Basel in a report on Monday, January 28th. They set a “buy” rating for the company.
Several hedge funds have recently added to or reduced their stakes in the company. QCI Asset Management Inc. NY grew its holdings in shares of Roche Holdings AG Basel by 15,631.4% in the fourth quarter. QCI Asset Management Inc. NY now owns 534,867 shares of the company’s stock valued at $16,624,000 after acquiring an additional 531,467 shares in the last quarter. Boston Common Asset Management LLC grew its holdings in Roche Holdings AG Basel by 1.5% during the fourth quarter. Boston Common Asset Management LLC now owns 502,667 shares of the company’s stock valued at $15,514,000 after purchasing an additional 7,535 shares during the period. Ferguson Wellman Capital Management Inc. grew its holdings in Roche Holdings AG Basel by 2.1% during the fourth quarter. Ferguson Wellman Capital Management Inc. now owns 328,776 shares of the company’s stock valued at $10,218,000 after purchasing an additional 6,720 shares during the period. Osher Van de Voorde Investment Management grew its holdings in Roche Holdings AG Basel by 0.5% during the fourth quarter. Osher Van de Voorde Investment Management now owns 259,128 shares of the company’s stock valued at $8,054,000 after purchasing an additional 1,276 shares during the period. Finally, Oak Associates Ltd. OH grew its holdings in Roche Holdings AG Basel by 15.4% during the fourth quarter. Oak Associates Ltd. OH now owns 194,125 shares of the company’s stock valued at $6,033,000 after purchasing an additional 25,890 shares during the period. 0.31% of the stock is owned by institutional investors.
RHHBY stock traded down $0.31 during trading on Friday, reaching $33.90. 332,392 shares of the stock were exchanged, compared to its average volume of 1,361,866. Roche Holdings AG Basel has a twelve month low of $26.30 and a twelve month high of $34.98. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.97 and a current ratio of 1.28. The company has a market cap of $231.57 billion, a P/E ratio of 14.61, a price-to-earnings-growth ratio of 2.66 and a beta of 0.52.
About Roche Holdings AG Basel
Roche Holding AG engages in the diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.
Recommended Story: Cost of Capital Explained
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.